Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial
1. Zilganersen shows positive results for treating Alexander disease in pivotal study. 2. Statistically significant improvement in gait speed observed after 61 weeks. 3. First investigational drug to demonstrate disease-modifying effects in AxD. 4. Ionis to submit a new drug application to the FDA in Q1 2026. 5. Share price rose 4.88% during premarket following positive study results.